UT-XLEAR
16.5.2022 16:02:14 CEST | Business Wire | Press release
Today Xlear announced a new partnership with Dr. Ferrer BioPharma (DFBP), which will make Xlear nasal spray the first nasal hygiene tool to deploy the GentleMist nozzle—the next generation nasal spray technology that research shows achieves better compound dispersion and coverage and a better user experience.
Nasal cleansing studies have found that rinsing the nose and nasal cavity is an important tool for improving health and wellbeing. Numerous clinical and lab studies have found that nasal hygiene is an important adjunct in countering rhinositus, as well as a range of bacterial and viral infections.
New research, published by The European Society of Medicine found that the GentleMist nozzle achieved more uniform and more complete dispersion of nasal sprays into the nose and nasal cavity. The study also found that the new nozzle was gentler and significantly improved the user experience over typical nose spray technologies. You can read the full study by clicking here: Evaluation of Patient Experience for a Computationally-Guided Intranasal Spray Protocol to Augment Therapeutic Penetration: Implications for Effective Treatments for COVID-19, Rhinitis, and Sinusitis | Medical Research Archives (esmed.org)
Traditionally nasal sprays have just had a standard pattern where the spray shoots straight up the airway in the direction it is sprayed. The new nozzle is very gentle and the spray is applied in a vortex/whirlpool pattern. This is extremely important and beneficial for Xlear and their customers as it allows Xlear’s mix (saline, xylitol and grapefruit seed extract) to be applied much more effectively and completely to the nose and nasal cavity.
“For more than twenty years, millions of people have been using and benefiting from our nasal spray and we are extremely excited to make this new technology available to them to improve their user experience. We realize that if washing our nose every morning and evening is uncomfortable, or irritating or hurts in even the slightest way we are not going to have people wash their nose enough to where it will make a difference. If it hurt us every time we washed our hands…or brushed our teeth, we wouldn’t be doing that enough either. Just like washing our hands, taking a shower and brushing our teeth, washing our nose is an added layer of protection to keeping us clean and healthy…and breathing better all day,” said Xlear CEO Nate Jones.
Xlear is not intended to diagnose, treat, cure or prevent any disease.
About Xlear
Founded in 2000, Xlear, Inc. is recognized as the leading manufacturer of natural, proactive health care products with xylitol. Xlear is committed to providing consumers with the highest quality products while striving to educate medical and dental professionals, as well their patients, about how using xylitol instead of sugar can help people live a much healthier and happy life. Xlear is supported by a team of doctors, hygienists and scientists who advocate the use and benefits of xylitol through continuous clinical research. Xlear, Inc. offers Xlear Nasal Spray, an award-winning, patented saline and xylitol nasal solution; a complete line of oral health products offered under the Spry Dental Defense System; and Lite&Sweet, a xylitol and erythritol sweetener used as a sugar substitute in cooking, baking and general consumption. For more information visit www.xlear.com .
About Dr. Ferrer BioPharma
Dr. Ferrer BioPharma are the leading innovators in intranasal medications to treat cough, colds, flu, and allergies. Dr. Ferrer BioPharma uses advanced nanoparticle technology to bring high-quality, evidence-based, consumer-focused, and doctor-invented products to the market. The mission is to provide to the market evidence-based therapies combining new ideas with proven concepts in the service of helping people. From molecules to the delivery of effective therapies to treat the populations we serve, Dr. Ferrer Biopharma is designing top-of-the-line intranasal treatments to help people breathe better. For more information visit www.drferrerbiopharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005266/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde
IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 22:15:00 CET | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/
Verimatrix ReAccess Earns Gold 2026 Merit Award for Telecom & Wireless2.3.2026 17:50:00 CET | Press release
Regulatory News: Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that its Verimatrix ReAccess solution was honored with a gold 2026 Merit Award for Telecom & Wireless. The industry accolade recognizes the company’s next-generation content security solution that modernizes legacy Conditional Access Systems (CAS) across DVB, IPTV and OTT networks without requiring costly hardware replacements or field service interventions. Judged by industry executives, media professionals and technology consultants, the Merit Awards evaluate submissions from across the telecommunications landscape. Verimatrix ReAccess enables secure, over-the-air (OTA) software updates to deployed set-top boxes (STBs), delivering operator cost savings, reduced operational complexity, and ongoing protection against piracy. It also empowers operators to continuously strengthen content security, eliminating the need for costly hardware replacements. U
Textron Aviation Launches Donation Campaign to Support 2026 Special Olympics Airlift; Continues Nationwide Call for Volunteer Doves2.3.2026 17:00:00 CET | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of a donation campaign benefitting Special Olympics in support of the 2026 Special Olympics Airlift, a nationwide effort that brings athletes and coaches to the Special Olympics USA Games through the generosity of volunteer pilots, aircraft owners and operators known as Doves. Financial contributions go directly to the Special Olympics, a 501(c)(3) charitable organization. New for the 2026 event, the donation campaign serves a vital role in ensuring each delegation has what it needs for a smooth and welcoming travel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302196418/en/ Textron Aviation launches donation campaign to support 2026 Special Olympics Airlift; continues nationwide call for volunteer Doves (Photo credit: Textron Aviation). “This campaign reflects the spirit of unity and generosity that defines the Special Olym
Forrester Announces The Agenda For Its 2026 CX Events To Help Address The Challenges AI Can’t Handle Alone2.3.2026 15:30:00 CET | Press release
The global event series will bring together customer experience, marketing, and digital business leaders at CX Forum East, CX Forum West, and CX Summit EMEA Forrester (Nasdaq: FORR) today announced the agenda for its global customer experience (CX) event series: CX Summit EMEA, being held in Amsterdam, June 8–10, 2026; CX Forum East, being held in New York City, June 16–17, 2026; and CX Forum West, being held in San Francisco, June 29–30, 2026. Today, CX, marketing, and digital business leaders are under mounting pressure to leverage AI to architect smarter end-to-end customer journeys, automate service, operationalize AI agents, and deliver true personalization at scale — all while consumer trust is at an all-time low. While AI is promising to raise the bar for speed and efficiency, beneath every customer experience is a foundation that AI alone can’t build. To forge trust, organizations need to embed human creativity, context, customer identity, and quality data into every customer i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
